Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

Anti-Cancer Drugs

Volumn 12, Issue 8, 2001, Pages 683-690

  Gieseg, Michael A ^a,b   De Bock, Charles ^a   Ferguson, Lynnette R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

CI 1033; Cisplatin; DNA repair; Epidermal growth factor receptor inhibitor; Synergy

Indexed keywords

CANERTINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELLS, CULTURED; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; LUCIFERASES; MICE; MORPHOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0034853561     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200109000-00007     Document Type: Article

References (39)

1. The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer
2. Epidermal growth factor-related peptides and their receptors in human malignancies
3. Epidermal growth factor receptor (EGFR) biology and human oral cancer
4. Epidermal growth factor receptor family and chemosensitization
5. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
6. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
7. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
8. Trastuzumab. A humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer
9. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastic breast cancer: Evidence for receptor-enhanced chemosensitivity
10. Trastuzumab
11. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
12. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
13. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
14. erb-2 is dependent on the ras signaling pathway
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
16. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
17. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
18. Low dose cisplatin can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR tyrosine kinase inhibitor (ZD1839; 'Iressa') in vivo
19. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
20. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
21. Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor
22. Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signalling through ErbB2, erbB3 and erbB4 by PD 158780 and PD 183805
23. A Phase 1 and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors
24. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
25. DNA excision repair pathways
26. Epidermal growth factor dependent transformation by a human EGF receptor proto-oncogene
27. New colorimetric cytotoxicity assay for anticancer-drug screening
28. Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells to cis-diamminedichloroplatinum(II)
29. Beta-galactosidase and choramphenicol acetyltransferase assays in 96-well plates
30. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
31. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
32. Mutagenic and carcinogenic properties of platinum-based anticancer drugs
33. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP
34. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcritpion factor human upstream binding factor
35. Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcritpion from the mouse mammary tumor virus promoter in vivo
36. Differential effects of cisplatin on the expression of chimeric marker genes in CV-1 cells
37. cis-diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: Potential involvement of a protein kinase C-dependent signaling pathway
38. Lack of cjun activity increases survival to cisplatin
39. Transformed cells require continous activity of RNA polymerase II to resist oncogene-induced apoptosis